{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.","groups":[{"description":"Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.","id":"OG000","title":"8 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG001","title":"12 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG002","title":"12 mg/kg Ramucirumab (Part B)"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)","title":"Number of Participants With Anti-Ramucirumab Antibodies","type":"PRIMARY","unitOfMeasure":"participants"}